Exelixis to Launch Fourth Quarter and Full Yr 2022 Monetary Outcomes on Tuesday, February 7, 2023

Read Time:2 Minute, 15 Second

Convention Name and Webcast to Observe at 5:00 p.m. ET / 2:00 p.m. PT –

ALAMEDA, Calif., January 24, 2023–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) introduced right now that its fourth quarter and full 12 months 2022 monetary outcomes shall be launched on Tuesday, February 7, 2023 after the markets shut. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis administration will host a convention name and webcast to debate the outcomes and supply a common enterprise replace. Entry to the occasion is accessible through the Web from the corporate’s web site.

To entry the webcast hyperlink, log onto www.exelixis.com and proceed to the Information & Occasions / Occasion Calendar web page below the Traders & Media heading. Please hook up with the corporate’s web site a minimum of quarter-hour previous to the convention name to make sure satisfactory time for any software program obtain that could be required to hearken to the webcast. Alternatively, please name 888-338-9509 (home) or 412-902-4281 (worldwide) and ask to be joined into the Exelixis convention name to take part by cellphone.

A phone replay shall be obtainable till 8:00 p.m. ET on February 9, 2023. Entry numbers for the phone replay are: 877-344-7529 (home) and 412-317-0088 (worldwide); the passcode is 7374267. A webcast replay may even be archived on www.exelixis.com for one 12 months.

About Exelixis

Exelixis is a globally formidable oncology firm innovating next-generation medicines and regimens on the forefront of most cancers care. Powered by bi-coastal facilities of discovery and growth excellence, we’re quickly evolving our product portfolio to focus on an increasing vary of tumor sorts and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and different biotherapeutics. This complete method harnesses many years of strong funding in our science and partnerships to advance our investigational applications and lengthen the affect of our flagship industrial product, CABOMETYX® (cabozantinib). Exelixis is pushed by a daring scientific pursuit to create transformational therapies that give extra sufferers hope for the long run. For details about the corporate and its mission to assist most cancers sufferers recuperate stronger and stay longer, go to www.exelixis.com, observe @ExelixisInc on Twitter, like Exelixis, Inc. on Fb and observe Exelixis on LinkedIn.

Exelixis, the Exelixis brand and CABOMETYX are registered U.S. emblems.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20230124006010/en/

Contacts

Traders Contact:
Susan Hubbard
Government Vice President,
Public Affairs & Investor Relations
Exelixis, Inc.
650-837-8194
[email protected]

Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
[email protected]

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Boston Celtics reminding us simply how good they are often at their greatest
Next post Bowers & Wilkins up to date its Pi7 and Pi5 earbuds with higher battery life